Boston Scientific Invests $1.5B in MiRus for Next-Gen TAVR Technology
Event summary
- Boston Scientific invested $1.5 billion for a 34% stake in MiRus LLC, gaining an exclusive option to acquire its TAVR system.
- The SIEGEL TAVR valve uses a proprietary rhenium alloy, making it nickel-free and potentially more durable than existing options.
- Boston Scientific could fully acquire MiRus for an additional $3 billion upon meeting clinical and regulatory milestones.
- The STAR pivotal trial, evaluating the SIEGEL valve in 1,025 patients, is currently underway.
The big picture
Boston Scientific's investment in MiRus reflects a strategic push into next-generation TAVR technology, an area with growing demand due to rising aortic stenosis cases. The deal underscores the company's focus on expanding its cardiovascular portfolio with innovative, differentiated solutions. The potential full acquisition highlights Boston Scientific's long-term commitment to integrating cutting-edge biomaterials and procedural advancements into its offerings.
What we're watching
- Clinical Validation
- How the STAR trial results will impact Boston Scientific's decision to fully acquire MiRus.
- Regulatory Approval
- The pace at which the SIEGEL TAVR system gains regulatory clearance for commercial use.
- Market Differentiation
- Whether the SIEGEL valve's design advantages can position it as a leader in the TAVR market.
Related topics